Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT03020797 · Stony Brook University · NA · terminated · last registry update 2023-05-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “1\) Enrolment below study target and 2) too many subjects had early termination due to disease progression.” | – | Registry record, Stony Brook University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GRIA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-19Results posted on the registry: Massachusetts General Hospital, Topiramate or Placebo (NCT00606411)
- 2024-04-04Phase 3 first posted: Kafrelsheikh University, Zonisamide 50 MG + Topiramate 50 MG (NCT06347497)
- 2024-02-08Phase 3 first posted: Kafrelsheikh University, Valproic acid + Topiramate 50 MG (NCT06248931)
- 2024-02-06Phase 3 first posted: Kafrelsheikh University, Lacosamide 50 MG + Topiramate 50Mg Tab (NCT06243692)
- 2023-12-14Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Perampanel + Placebo (NCT04309721)
- 2023-11-18Results posted on the registry: VA Office of Research and Development, topiramate + placebo (NCT03176953)
- 2023-11-14Results posted on the registry: Virginia Commonwealth University, topiramate (NCT02878798)
- 2023-10-26Also stopped (withdrawn): University of Minnesota, Qsymia and lifestyle management therapy (NCT05834062)
- 2023-09-15Results posted on the registry: Eisai Inc., perampanel (NCT02914314)
- 2023-08-18Results posted on the registry: Virginia Commonwealth University, Perampanel + Placebo (NCT02120365)
- 2023-07-24Phase 3 first posted: Lady Hardinge Medical College, Topiramate (NCT05958160)
- 2023-07-18Results posted on the registry: Mayo Clinic, Phentermine-Topiramate + Liraglutide (NCT03374956)
- 2023-07-03Results posted on the registry: Weill Medical College of Cornell University, Perampanel 6 MG (NCT03653741)
- 2023-06-22Results posted on the registry: Mayo Clinic, Anticonvulsant Agent + Perampanel (NCT04650204)
- 2023-06-22Also stopped (terminated): Mayo Clinic, Anticonvulsant Agent + Perampanel (NCT04650204)
- 2023-06-22Results posted on the registry: Mayo Clinic, Phentermine-Topiramate Extended Release + Placebo (NCT04408586)
- 2023-03-23Results posted on the registry: VA Office of Research and Development, Topiramate + placebo (NCT03018704)
- 2023-03-23Also stopped (terminated): VA Office of Research and Development, Topiramate + placebo (NCT03018704)
- 2023-02-28Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05748483)
- 2023-02-14Also stopped (terminated): Hartford Hospital, Administration of weight loss drug (Metformin or Topiramate) (NCT03603080)
- 2022-10-07Results posted on the registry: Virginia Commonwealth University, Perampanel Tablet + Disulfiram (NCT04502589)
- 2022-09-10Results posted on the registry: VIVUS LLC, VI-0521 oral capsule + Placebo oral capsule (NCT03922945)
- 2022-07-13Results posted on the registry: University of Colorado, Denver, Topiramate (NCT03335163)
- 2022-06-27Also stopped (withdrawn): Assistance Publique Hopitaux De Marseille, Perampanel + conventional antiepileptic treatment (NCT03636958)
- 2022-05-16Results posted on the registry: Eisai Inc., Perampanel (NCT03288129)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision